Shield Therapeutics plc (AIM:STX)
7.05
-0.15 (-2.08%)
Sep 29, 2025, 4:23 PM GMT+1
Shield Therapeutics Revenue
Shield Therapeutics had revenue of $21.45M USD in the half year ending June 30, 2025, with 472.99% growth. This brings the company's revenue in the last twelve months to $41.50M, up 93.23% year-over-year. In the year 2024, Shield Therapeutics had annual revenue of $32.18M with 145.93% growth.
Revenue (ttm)
$41.50M
Revenue Growth
+93.23%
P/S Ratio
2.52
Revenue / Employee
$658.65K
Employees
63
Market Cap
76.44M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 32.18M | 19.10M | 145.93% |
Dec 31, 2023 | 13.09M | 7.59M | 137.95% |
Dec 31, 2022 | 5.50M | 3.44M | 167.35% |
Dec 31, 2021 | 2.06M | -12.12M | -85.50% |
Dec 31, 2020 | 14.18M | 13.23M | 1,389.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Shield Therapeutics News
- 8 months ago - UK Stock Market News: GSK, DCC, Shield Therapeutics - The Armchair Trader
- 11 months ago - Small Cap Stocks: Microsalt, Proton Motor Power, Eckoh - The Armchair Trader
- 1 year ago - Small Cap Stocks: Seascape Energy, Arkle, Mirriad - The Armchair Trader
- 4 years ago - OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX - PRNewsWire